RhumbLine Advisers’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.02M | Buy |
336,939
+15,785
| +5% | +$141K | ﹤0.01% | 1665 |
|
|
2025
Q1 | $2.41M | Buy |
321,154
+12,022
| +4% | +$90.2K | ﹤0.01% | 1721 |
|
|
2024
Q4 | $2.32M | Buy |
309,132
+5,615
| +2% | +$42.2K | ﹤0.01% | 1806 |
|
|
2024
Q3 | $2.31M | Sell |
303,517
-15,148
| -5% | -$115K | ﹤0.01% | 1826 |
|
|
2024
Q2 | $1.97M | Buy |
318,665
+18,916
| +6% | +$117K | ﹤0.01% | 1894 |
|
|
2024
Q1 | $1.52M | Buy |
299,749
+5,098
| +2% | +$25.9K | ﹤0.01% | 2042 |
|
|
2023
Q4 | $1.76M | Sell |
294,651
-684
| -0.2% | -$4.1K | ﹤0.01% | 1968 |
|
|
2023
Q3 | $2.09M | Sell |
295,335
-18,559
| -6% | -$131K | ﹤0.01% | 1835 |
|
|
2023
Q2 | $2.21M | Buy |
313,894
+2,825
| +0.9% | +$19.9K | ﹤0.01% | 1843 |
|
|
2023
Q1 | $2.59M | Buy |
311,069
+2,538
| +0.8% | +$21.2K | ﹤0.01% | 1675 |
|
|
2022
Q4 | $3.54M | Buy |
308,531
+9,481
| +3% | +$109K | ﹤0.01% | 1487 |
|
|
2022
Q3 | $3.77M | Buy |
299,050
+19,850
| +7% | +$250K | 0.01% | 1392 |
|
|
2022
Q2 | $2.95M | Sell |
279,200
-11,420
| -4% | -$121K | ﹤0.01% | 1550 |
|
|
2022
Q1 | $4.73M | Sell |
290,620
-22,648
| -7% | -$368K | 0.01% | 1352 |
|
|
2021
Q4 | $4.34M | Buy |
313,268
+2,509
| +0.8% | +$34.8K | 0.01% | 1436 |
|
|
2021
Q3 | $4.47M | Buy |
310,759
+7,449
| +2% | +$107K | 0.01% | 1424 |
|
|
2021
Q2 | $4.8M | Buy |
303,310
+36,843
| +14% | +$582K | 0.01% | 1452 |
|
|
2021
Q1 | $2.71M | Sell |
266,467
-32,020
| -11% | -$326K | ﹤0.01% | 1760 |
|
|
2020
Q4 | $2.22M | Buy |
298,487
+32,992
| +12% | +$246K | ﹤0.01% | 1800 |
|
|
2020
Q3 | $912K | Sell |
265,495
-10,754
| -4% | -$36.9K | ﹤0.01% | 2030 |
|
|
2020
Q2 | $1.32M | Buy |
276,249
+87,541
| +46% | +$417K | ﹤0.01% | 1929 |
|
|
2020
Q1 | $377K | Buy |
188,708
+4,539
| +2% | +$9.07K | ﹤0.01% | 2291 |
|
|
2019
Q4 | $635K | Buy |
184,169
+9,107
| +5% | +$31.4K | ﹤0.01% | 2265 |
|
|
2019
Q3 | $502K | Buy |
175,062
+13,631
| +8% | +$39.1K | ﹤0.01% | 2325 |
|
|
2019
Q2 | $612K | Buy |
161,431
+11,896
| +8% | +$45.1K | ﹤0.01% | 2273 |
|
|
2019
Q1 | $1.22M | Sell |
149,535
-339
| -0.2% | -$2.76K | ﹤0.01% | 1944 |
|
|
2018
Q4 | $1.21M | Buy |
149,874
+55,789
| +59% | +$450K | ﹤0.01% | 1913 |
|
|
2018
Q3 | $718K | Sell |
94,085
-895
| -0.9% | -$6.83K | ﹤0.01% | 2136 |
|
|
2018
Q2 | $544K | Buy |
94,980
+3,235
| +4% | +$18.5K | ﹤0.01% | 2268 |
|
|
2018
Q1 | $438K | Buy |
91,745
+9,950
| +12% | +$47.5K | ﹤0.01% | 2266 |
|
|
2017
Q4 | $402K | Sell |
81,795
-13,663
| -14% | -$67.2K | ﹤0.01% | 2327 |
|
|
2017
Q3 | $500K | Buy |
95,458
+1,155
| +1% | +$6.05K | ﹤0.01% | 2304 |
|
|
2017
Q2 | $524K | Buy |
94,303
+6,835
| +8% | +$38K | ﹤0.01% | 2268 |
|
|
2017
Q1 | $735K | Buy |
87,468
+2,740
| +3% | +$23K | ﹤0.01% | 2074 |
|
|
2016
Q4 | $536K | Buy |
84,728
+3,418
| +4% | +$21.6K | ﹤0.01% | 2189 |
|
|
2016
Q3 | $359K | Sell |
81,310
-19,144
| -19% | -$84.5K | ﹤0.01% | 2383 |
|
|
2016
Q2 | $285K | Buy |
100,454
+14,377
| +17% | +$40.8K | ﹤0.01% | 2566 |
|
|
2016
Q1 | $244K | Buy |
86,077
+3,245
| +4% | +$9.2K | ﹤0.01% | 2638 |
|
|
2015
Q4 | $855K | Buy |
82,832
+9,220
| +13% | +$95.2K | ﹤0.01% | 1911 |
|
|
2015
Q3 | $839K | Sell |
73,612
-2,922
| -4% | -$33.3K | ﹤0.01% | 1885 |
|
|
2015
Q2 | $1.14M | Sell |
76,534
-540
| -0.7% | -$8.07K | ﹤0.01% | 1785 |
|
|
2015
Q1 | $696K | Buy |
77,074
+7,990
| +12% | +$72.2K | ﹤0.01% | 2089 |
|
|
2014
Q4 | $840K | Buy |
69,084
+4,929
| +8% | +$59.9K | ﹤0.01% | 1932 |
|
|
2014
Q3 | $627K | Sell |
64,155
-2,380
| -4% | -$23.3K | ﹤0.01% | 2071 |
|
|
2014
Q2 | $848K | Buy |
+66,535
| New | +$848K | ﹤0.01% | 1937 |
|